|
||
| |||||||
|
Introduction: Although it is clear that angiogenesis inhibitors hold great potential for cancer management, the precise role, the most effective route to the market and the sales potential for these novel pharmacotherapies is unclear. Datamonitor’s research into the angiogenesis inhibitors forecasts the future role for these agents and their influence on shaping cancer therapy over the next ten years and beyond. Scope: * Opinion Leader interviews, discussing the likely evolution of the innovatives market, and high-profile angiogenesis inhibitors * Profiles and potential of key innovative agents in late-stage development * Case scenarios illustrating the opportunities and threats faced by developers of angiogenesis inhibitors along the path to commercialization * Market and agent forecasts to 2011 Report Highlights: Angiogenesis inhibitors, after some disappointing early results, still have potential as effective cytostatic agents. Developers of these agents must show synergy with cytotoxics to achieve significant market penetration, leading to a potential future role as long-term chronic therapy. Reasons to Purchase: * Identify which angiogenesis inhibitors are rated highly by opinion leaders, and which are not. * Determine the price level of your product by assessing its positioning relative to marketed products, and other pipeline agents * Evaluate key angiogenesis inhibitors in late-stage development for lung cancer to enhance your commercial positioning of your product Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a254 |
|
|
